Advancements in large drug molecule discovery and development over the past decade has enabled targeting various diseases via leveraging immunotherapeutic as well as cell and gene therapy strategies.
Structure, specific activity, and maintenance of potency of a large drug molecule are critical quality attributes that require characterization and monitoring during the late drug discovery workflow to minimize risks during drug development.
Solutions from PerkinElmer support a wide spectrum of applications along the workflows from late drug discovery through downstream characterization of either a protein biologic, viral or nucleic acid vector.
